首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1463269

全球多重检测市场规模、份额、成长分析、按产品、类型、技术、应用 - 产业预测 2024-2031

Global Multiplex Assay Market Size, Share, Growth Analysis, By Product, By Type, By Technology, By Application - Industry Forecast 2024-2031

出版日期: 2024年04月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球多重检测市场规模约20.5亿美元，预计将从2023年的23.5亿美元增至2031年的70.8亿美元，预测期内（2024-2031年）复合年增长率为14.77% 。

推动全球多重检测市场的主要因素是传染病和慢性病的盛行率不断上升、多重检测相对于单一多重检测和传统检测的主要优势、多重检测在伴随诊断中使用的增长以及早期诊断意识的不断提高。

根据目前药物审批情况预测，伴随诊断预计将在不久的将来大幅扩展。例如，FDA 授权罗氏于 2021 年 8 月销售伴随诊断产品，以发现可从抗 PD-1 免疫疗法中受益的患者的 dMMR 实体瘤。因此，伴随诊断的扩展可以大大促进全球市场的成长。早期诊断可以提高许多慢性疾病患者的生活质量，包括癌症，其存活率可提高三倍。早期发现还可以降低长期疾病的成本并增加可获得的治疗范围。

2021 年 7 月在 Avalere 发表的一份报告指出，当疾病扩散到身体其他部位并降低生存可能性时，36% 至 53% 的非小细胞肺癌、胃癌和胰腺癌患者被诊断患有第4 期癌症。如果非小细胞肺癌、胃癌和胰臟癌在早期被发现，5年存活率可以提高一倍。这些差异正在提高人们对早期疾病诊断价值的认识，并可能对整个预计时间内的市场成长产生重大影响。分子和蛋白质诊断中生物标记的验证不断增加，加上对自动化系统和高通量测试的需求不断增长，将进一步带来市场扩张的机会。

多种生物标记分析在神经系统疾病、自体免疫疾病和癌症的研究中有着广泛的应用。随着如此多的生物标记被发现和验证，很可能会开发出新的诊断方法。多重测试可用于定量评估蛋白质，以识别生物标记。这些测定允许使用统计上显着数量的样品和对照来评估几种潜在的蛋白质生物标记。因此，多重检测在生物标记验证中的应用提高了提供可靠资料的效率和速度，从而促进了短期市场扩张。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Agilent Technologies, Inc.
Luminex Corporation
Merck KGaA
QIAGEN NV
Roche Diagnostics
Randox Laboratories Ltd.
Bio-Techne Corporation
Abcam plc
GenScript Biotech Corporation
Mesoscale Discovery, LLC
Seegene Inc.
Becton, Dickinson and Company
Fluidigm Corporation
Meso Scale Diagnostics, LLC
PerkinElmer, Inc.
Siemens Healthineers AG
Biocartis NV

简介目录

Product Code: SQMIG35H2180

Global Multiplex Assay Market size was valued at around 2.05 billion in 2022 and is expected to rise from USD 2.35 billion in 2023 to reach a value of USD 7.08 Billion by 2031, at a CAGR of 14.77 % over the forecast period (2024-2031).

The primary factors driving the global multiplex assay market are the increasing prevalence of infectious and chronic diseases, the key benefits of multiplex assays over single plex and conventional assays, the growth of multiplex assay use in companion diagnostics, and the rising awareness of early diagnosis.

Predicted on current drug approval scenarios, companion diagnostics is expected to significantly expand in the near future. For example, the FDA authorized Roche to sell companion diagnostics in August 2021 to find dMMR solid tumors in patients who would benefit from anti-PD-1 immunotherapy. Therefore, the growth of the global market can be significantly aided by the expansion of companion diagnostics. Early diagnosis can enhance a patient's quality of life in many chronic diseases, including cancer, where there is a threefold increase in survival rate. Early detection can also reduce the cost of long-term illnesses and increase the spectrum of accessible therapies.

An report published in Avalere in July 2021 states that by the time the disease has spread to other body areas and decreased the likelihood of survival, between 36% and 53% of patients with non-small cell lung cancer, stomach cancer, and pancreatic cancer are diagnosed with stage 4 cancer. If non-small-cell lung cancer, stomach cancer, and pancreatic cancer are detected in their early stages, the 5-year survival rate can double. These differences are increasing awareness of the value of early disease diagnosis and could have a major impact on market growth throughout the projected period of time. The increasing validation of biomarkers in molecular and protein diagnostics, coupled with the growing demand for automated systems and high-throughput tests, will further present opportunities for market expansion.

Numerous applications of multiple biomarker analysis can be found in the research of neurological diseases, autoimmune diseases, and cancer. With so many biomarkers being discovered and validated, it is highly likely that new diagnoses will be developed. A multiplex test can be used to assess proteins quantitatively in order to identify biomarkers. These assays allow evaluation of several potential protein biomarkers using statistically significant quantities of samples and controls. As a result, the application of multiplex assays in biomarker validation improves the efficiency and speed at which reliable data may be delivered, thereby fostering short-term market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiplex Assay Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiplex Assay Market Segmental Analysis

The global multiplex assay market is segmented based on product, type, technology, application, process and region. Based on product the market is segmented into consumables, instruments and software. In terms of type, the market is segmented into protein multiplex assays, planar protein assays, bead-based protein assays, nucleic acid multiplex assays, planar protein assays, bead-based protein assays, and cell-based multiplex assays. Further classification of technology segments include flow cytometry, fluorescence detection, luminescence, multiplex real-time PCR, and other technologies. Based on application the market is segmented into research & development and clinical diagnostics. Based on end-users the market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and other end-users. Based on region the global multiplex assay market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Multiplex Assay Market

Multiplex assay demand is being driven by the increasing need for personalized medication. Multiple biomarkers can be measured simultaneously with these assays, improving patient classification and enabling more individualized treatment choices.

Restraints in the Global Multiplex Assay Market

Multiplex assays' acceptance may be constrained by the regulatory issues they raise. Regulatory clearance for these assays is necessary, and it can be expensive and time-consuming.

Market Trends of the Global Multiplex Assay Market

Growing use of multiplex immunoassays: Because multiplex immunoassays can test many proteins in a single sample, there is a growing demand for these assays. Drug discovery, diagnostic testing, and biomarker identification all make extensive use of these assays.

Increasing use of microarrays: Because microarray technology can assess numerous analytes at once, it is becoming more and more popular in the multiplex assay market. Drug discovery, proteomics, and genomes all make extensive use of microarrays.

Next-generation sequencing (NGS) technology development: Because NGS technologies can sequence a large number of genes or DNA fragments at once, they are being used more often in multiplex experiments. Personalized medicine, diagnostic testing, and genomics research all make extensive use of NGS technologies.

Growing requirement for point-of-care testing (POCT): The need for quick and precise diagnostic testing is driving the demand for POCT. Because multiplex assays allow for the simultaneous detection of numerous analytes in a single sample, they are a good fit for point-of-care testing.

Precision medicine is becoming more and more popular. It is a new area that focuses on tailoring medical care to a patient's genetic composition, lifestyle, and surroundings. Precision medicine benefits greatly from multiplex assays since they allow for the evaluation of several biomarkers in one sample, resulting in individualized treatment options.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Multiplex Assay Market by Product

Market Overview
Consumables
Instruments and Software

Global Multiplex Assay Market by Type

Market Overview
Protein Multiplex Assays
Nucleic Acid Multiplex Assays
Cell-based Multiplex Assays

Global Multiplex Assay Market by Technology

Market Overview
Flow Cytometry
Fluorescence Detection
Luminescence
Multiplex Real-time PCR
and Other Technologies

Global Multiplex Assay Market by Application

Market Overview
Research & Development
and Clinical Diagnostics

Global Multiplex Assay Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luminex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Randox Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Techne Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abcam plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenScript Biotech Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoscale Discovery, LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seegene Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fluidigm Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meso Scale Diagnostics, LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments